AbbVie (ABBV) Q4 2020 earnings summary

Executive summary

• Completed the Allergan acquisition, adding scale, 30+ brands and new therapeutic areas; the combined business ranked as the world’s fifth-largest biopharmaceutical company.

• 2020 priorities included maintaining medicine supply through COVID-19, advancing R&D, and expanding patient and community support.

Financial highlights

• Net revenues were $45.8B in 2020; reported figures include Allergan.

• Adjusted R&D investment was $5.8B, excluding specified items.

Outlook and guidance

• More than a dozen new product or indication approvals were anticipated over the following two years, including five expected in 2021.

• The pipeline included 90+ compounds, devices or indications in development, with 50+ in mid- and late-stage development.